Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.
Marc-André Gagnon dispels misconceptions about the benefits of private health insurance plans and argues in favour of a universal model for pharmacare.
Andrea Frydl cautions Canadians about the harms of direct-to-consumer advertising for pharmaceuticals and offers advice for health care providers and policy makers.
Chelsea Cox comments on the introduction of two clean needle exchange pilot programs in Canadian prisons.
Matthew Herder considers possible regulatory responses to the opioid epidemic that aim to recover health care costs, compensate survivors, or prosecute pharmaceutical companies.
Martha Paynter reasons that the parent-infant benefits of breastfeeding/chestfeeding outweigh concerns about drug regimens that facilitate transgender women’s lactation.